# Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)

> **NCT00161993** · PHASE2 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 24 (actual)

## Conditions studied

- Primary Immunodeficiency Diseases (PID)
- Agammaglobulinemia
- Hypogammaglobulinemia

## Interventions

- **DRUG:** Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution
- **DRUG:** Gammagard S/D (Solvent/Detergent)

## Key facts

- **NCT ID:** NCT00161993
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06-13
- **Primary completion:** 2003-09-24
- **Final completion:** 2003-09-24
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00161993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00161993, "Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00161993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*